Lilly’s Taltz-Zepbound Combo Yields 27.1% PASI 100 and ≥10% Weight Loss
At 36 weeks in the TOGETHER-PsO Phase 3b trial, Lilly’s Taltz plus Zepbound combo enabled 27.1% of patients to achieve complete skin clearance (PASI 100) and ≥10% weight loss versus 5.8% with Taltz alone (p<0.001). The regimen also raised PASI 100 response by 40% (40.6% vs 29.0%, p<0.05).
1. Trial Design and Participants
The TOGETHER-PsO Phase 3b trial randomized 274 adults with moderate-to-severe plaque psoriasis and obesity or overweight (mean BMI >39 kg/m2) in a 1:1 open-label design to receive Taltz alone or alongside Zepbound for 52 weeks, with primary analysis at Week 36.
2. Efficacy Results
At Week 36, 27.1% of the combination arm achieved both complete skin clearance (PASI 100) and ≥10% weight reduction versus 5.8% with Taltz monotherapy (p<0.001). The combo also delivered a 40% relative increase in PASI 100 response (40.6% vs 29.0%, p<0.05), highlighting dual-disease impact.
3. Safety Profile and Next Steps
Adverse events in the combination arm were generally mild to moderate, with nausea, diarrhea and injection-site reactions among the most common. Lilly plans peer-reviewed publication of detailed 36-week data and discussions with regulators on potential label expansion for concomitant use.